240 related articles for article (PubMed ID: 8607114)
1. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice.
Declerck PJ; Verstreken M; Collen D
Thromb Haemost; 1995 Nov; 74(5):1305-9. PubMed ID: 8607114
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody-based immunoassays for the specific quantitation of rat PAI-1 antigen and activity in biological samples.
Ngo TH; Verheyen S; Knockaert I; Declerck PJ
Thromb Haemost; 1998 Apr; 79(4):808-12. PubMed ID: 9569197
[TBL] [Abstract][Full Text] [Related]
3. An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA.
Declerck PJ; Van Keer L; Verstreken M; Collen D
Thromb Haemost; 1992 Jan; 67(1):95-100. PubMed ID: 1377417
[TBL] [Abstract][Full Text] [Related]
4. Immunoassays for the quantitation of porcine PAI-1 antigen and activity in biological fluid samples.
Leng HM; Brouwers E; Knockaert I; Declerck PJ
Thromb Haemost; 2000 Dec; 84(6):1082-6. PubMed ID: 11154117
[TBL] [Abstract][Full Text] [Related]
5. Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice.
Lijnen HR; Moons L; Beelen V; Carmelie P; Collen D
Thromb Haemost; 1995 Oct; 74(4):1126-31. PubMed ID: 8560424
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
7. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies.
Darras V; Thienpont M; Stump DC; Collen D
Thromb Haemost; 1986 Dec; 56(3):411-4. PubMed ID: 3105111
[TBL] [Abstract][Full Text] [Related]
8. Immunological quantitation of rabbit plasminogen activator inhibitor-1 in biological samples: evidence that rabbit platelets do not contain PAI-1.
Ngo TH; Declerck PJ
Thromb Haemost; 1999 Nov; 82(5):1510-5. PubMed ID: 10595646
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes.
Lijnen HR; Wagner EF; Collen D
Thromb Haemost; 1997 Feb; 77(2):362-7. PubMed ID: 9157597
[TBL] [Abstract][Full Text] [Related]
10. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA.
Holvoet P; Cleemput H; Collen D
Thromb Haemost; 1985 Oct; 54(3):684-7. PubMed ID: 3937265
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.
Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS
Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623
[TBL] [Abstract][Full Text] [Related]
12. The plasminogen-activating system in gingival fluid from adults. An intra-individual study before and after treatment of gingivitis.
Kinnby B; Matsson L; Lecander I
Scand J Dent Res; 1994 Dec; 102(6):334-41. PubMed ID: 7871356
[TBL] [Abstract][Full Text] [Related]
13. Increased basal levels of free plasminogen activator activity found in human aqueous humor.
Wang Y; Taylor DM; Smalley DM; Cone RE; O'Rourke J
Invest Ophthalmol Vis Sci; 1994 Aug; 35(9):3561-6. PubMed ID: 8056534
[TBL] [Abstract][Full Text] [Related]
14. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
Matsuno H; Kozawa O; Niwa M; Ueshima S; Matsuo O; Collen D; Uematsu T
Thromb Haemost; 1999 Apr; 81(4):601-4. PubMed ID: 10235447
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
16. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
Grøndahl-Hansen J; Agerlin N; Munkholm-Larsen P; Bach F; Nielsen LS; Dombernowsky P; Danø K
J Lab Clin Med; 1988 Jan; 111(1):42-51. PubMed ID: 3121772
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
[TBL] [Abstract][Full Text] [Related]
18. Modulation of sympathetic activity by tissue plasminogen activator is independent of plasminogen and urokinase.
Schaefer U; Vorlova S; Machida T; Melchor JP; Strickland S; Levi R
J Pharmacol Exp Ther; 2007 Jul; 322(1):265-73. PubMed ID: 17429057
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
Landau BJ; Kwaan HC; Verrusio EN; Brem SS
Cancer Res; 1994 Feb; 54(4):1105-8. PubMed ID: 8313368
[TBL] [Abstract][Full Text] [Related]
20. A specific immunologic assay for functional plasminogen activator inhibitor 1 in plasma--standardized measurements of the inhibitor and related parameters in patients with venous thromboembolic disease.
Philips M; Juul AG; Selmer J; Lind B; Thorsen S
Thromb Haemost; 1992 Nov; 68(5):486-94. PubMed ID: 1455392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]